Days after going public, Viela Bio Inc. nailed down a deal with Mitsubishi Tanabe Pharma Corp. to develop and commercialize Viela’s humanized anti-CD19 monoclonal antibody, inebilizumab, in nine Asia regions for the rare disease called neuromyelitis optica spectrum disorder (NMOSD), as well as other potential future indications.
HONG KONG – South Korean pharmaceutical company Chong Kun Dang Holdings recently invested KRW5 billion (US$4.1 million) in Biorchestra Co. Ltd., a Korean startup based in Daejeon that aims to develop Alzheimer’s dementia treatment based on microRNA.
HONG KONG – Taiwan's National Health Insurance Administration has added Gilead Sciences Inc.'s Biktarvy (bictegravir + emtricitabine + tenofovir alafenamide), a once-daily single tablet for the treatment of adults with HIV-1, to its list of reimbursed medicines.
HONG KONG – I-Mab Biopharma (Shanghai) Co. Ltd. has received IND approval from China's National Medical Products Administration (NMPA) for its CD73 antibody, getting the go-ahead for a phase I/II trial of TJD-5 in patients with advanced solid tumors.
HONG KONG – Singapore's Aslan Pharmaceuticals Ltd. and South Korea's Bukwang Pharmaceutical Co. Ltd. have jointly established a new company dedicated to the development of aryl hydrocarbon receptor (AhR) drug candidates. Named Jaguahr Therapeutics Pte. Ltd. – the unusual spelling a clear reference to "AhR" – it will be based in Singapore and will focus on developing immuno-oncology therapeutics for global markets based on the preclinical AhR antagonists in Aslan's early stage pipeline.
PERTH, Australia – Australia is at risk of falling behind the U.S. and Europe in preventing recurrence of melanoma, the Melanoma Institute Australia warns. It is urging the Australian government to undertake a timely review of immunotherapy treatments effective in preventing the spread of melanoma and to fast track listings on the government-subsidized Pharmaceutical Benefits Scheme (PBS).
HONG KONG – GI Innovation Inc., a microbiome combination drug developer based in Seoul, South Korea, has recently issued fully paid convertible preferred stock (CPS) worth KRW37.5 billion (US$31 million) for a series B investment.
The Asia Pacific region (APAC) is vast and awash with varied economies, languages, governments and ambitions. That's the backdrop for its dramatic underperformance compared to the West's pharmaceutical innovations. Yet plenty of opportunities exist, along with a healthy dose of uncertainty, according to the first Pharmaceutical Innovation in the APAC region report, published by Clarivate Analytics plc.
RSS